Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,Hepatology
Link
http://www.nature.com/articles/ajg201666.pdf
Reference5 articles.
1. Vedolizumab and infliximab combination therapy in the treatment of Crohns disease.;Hirten;Am J Gastroenterol,2015
2. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.;Freling;Am J Gastroenterol,2015
3. Efficacy and safety of ustekinumab, a human interleukin-1223 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).;Leonardi;Lancet,2008
4. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon--expressing Th1 cells and IL-17AIL-22-expressing Th17 cells and respond to anti-IL-12IL-23 antibody treatment.;Tillack;Gut,2014
5. Ustekinumab induction and maintenance therapy in refractory Crohns disease.;Sandborn;N Engl J Med,2012
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities;Clinical and Translational Medicine;2024-03
2. Dual biological therapy and small molecules in pediatric inflammatory bowel disease;Pharmacological Research;2023-10
3. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies;Biomedicine & Pharmacotherapy;2023-02
4. Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease;Diseases;2022-11-09
5. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment);Gut;2022-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3